Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02176720 · ClinicalTrials.gov registry record · Phase 1
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
A Phase 1 study, sponsored by The Methodist Hospital Research Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT02176720 is a Phase 1 study that was terminated before completion, run by The Methodist Hospital Research Institute. The registered enrollment target is 31 participants.
The verdict
NCT02176720, a Phase 1 study, was terminated before completion, sponsored by The Methodist Hospital Research Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
It was previously shown that \[18F\]Fluorodopa (FDOPA) PET imaging results in intended management changes in 41% of brain tumor patients. However, its impact on patient outcome defined as survival, costs, and/or quality of life has not been demonstrated. Regulatory agencies require randomized trials to determine the impact of PET on patient management and outcome. In this study we hypothesize that the addition of FDOPA PET will improve patient outcome by more accurately identifying presence or absence of tumor recurrence than conventional imaging.
Interventions
- DRUG FDOPA PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02176720
The ClinicalTrials.gov registry entry for NCT02176720 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FDOPA PET is the first listed.
NCT02176720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02176720 about?
NCT02176720 is a clinical study titled "Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma". It was previously shown that \[18F\]Fluorodopa (FDOPA) PET imaging results in intended management changes in 41% of brain tumor patients. However, its impact on patient outcome defined as survival, costs, and/or quality of life has not been demonstrated. Regulatory agencies require randomized trials...
What is the current status of trial NCT02176720?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2014-05. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02176720?
The interventions under investigation include: FDOPA PET (DRUG).
Who is sponsoring clinical trial NCT02176720?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.